News
ARGX
901.17
-1.62%
-14.80
argenx Is Maintained at Overweight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1110
Benzinga · 3d ago
ARGX Quantitative Stock Analysis - Benjamin Graham
NASDAQ · 5d ago
Weekly Report: what happened at ARGX last week (1124-1128)?
Weekly Report · 6d ago
Looking Into argenx SE's Recent Short Interest
Benzinga · 11/28 15:00
argenx: Sights Set On $1,000
Seeking Alpha · 11/26 16:15
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Benzinga · 11/24 12:49
argenx Cut to Peer Perform From Outperform by Wolfe Research
Dow Jones · 11/24 11:09
Wolfe Research Downgrades argenx to Peer Perform
Benzinga · 11/24 11:00
Argenx downgraded to Peer Perform from Outperform at Wolfe Research
TipRanks · 11/24 10:41
Weekly Report: what happened at ARGX last week (1117-1121)?
Weekly Report · 11/24 09:38
Guru Fundamental Report for ARGX - Benjamin Graham
NASDAQ · 11/20 21:00
argenx SE Shareholders Approve Remuneration Policy at Extraordinary Meeting
TipRanks · 11/18 22:31
arGEN-X SE Held Extraordinary General Meeting of Shareholders
Reuters · 11/18 21:01
Baron Opportunity Fund Q3 2025 Portfolio Update
Seeking Alpha · 11/18 15:06
argenx Announces Results of Extraordinary General Meeting of Shareholders
Barchart · 11/18 15:01
HQH: Seeing Strong Recent Returns While Attractively Discounted
Seeking Alpha · 11/17 15:24
argenx Price Target Raised to $1124.00/Share From $1041.00 by Citigroup
Dow Jones · 11/17 15:20
argenx Is Maintained at Buy by Citigroup
Dow Jones · 11/17 15:20
Citigroup Maintains Buy on argenx, Raises Price Target to $1124
Benzinga · 11/17 15:11
More
Webull provides a variety of real-time ARGX stock news. You can receive the latest news about Argenx Se through multiple platforms. This information may help you make smarter investment decisions.
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.